Objective: We investigated whether bioimaging for Parkinson’s disease (PD) such as metaiodobenzylguanidine (MIBG) myocardial scintigraphy and 123I-ioflupane SPECT (DaTSPECT) are useful for biomarker of sleep disturbances in PD or not.

Background: Sleep disturbances are very common as non-motor symptoms in PD. The degree of sleep disturbance is usually estimated using questionnaire. To date, the data of MIBG myocardial scintigraphy and DaTSPECT are used for the diagnosis of PD but not used for assessment of sleep disturbances.

Method: 66 patients with PD who have already examined by MIBG myocardial scintigraphy, DaTSPECT and questionnaire about sleep disturbances in clinical practice intended for this study. As questionnaire about sleep disturbances, Parkinson’s disease sleep scale 2 (PDSS-2) and Epworth sleepiness scale (ESS) were used to assess nighttime sleep problems and excessive daytime sleepiness, respectively. In DaTSPECT, we used two different quantification vales for RI accumulation in striatum. One is specific binding ratio (SBR) by DaTView, and the other is striatum uptake ratio (SUR) by DaTQUANT.

Results: Neither total score of PDSS-2 nor total score of ESS correlated with H/M ratio of MIBG myocardial scintigraphy. However score of sleep specific symptoms which is sub-items in PDSS-2 significantly correlated with H/M ratio. Neither total score of PDSS-2 nor total score of ESS correlated with each quantification vale of DaTSPECT.

Conclusion: It is possible that PD patients with remarkable decreased H/M ratio of MIBG myocardial scintigraphy tend to emerge sleep disturbances such as difficulty falling asleep, uninterrupted sleep and unrefreshing sleep.

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/association-between-sleep-disturbances-in-parkinsons-disease-and-bioimaging/